Drug Trial Radar · NCT06598735
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Nov 5, 2024
Primary completion
Dec 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS-4508 in subjects with advanced or metastatic solid tumors and explore the reasonable dosage of HRS-4508.
Conditions
- Advanced Solid Tumors
Interventions
HRS-4508Drug
HRS-4508
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoints: Number of subjects with adverse events and the severity of adverse eventsTime frame: every 4 weeks after treatment initiation (through study completion, an average 5 mouths)
- DLT (Dose-limiting toxicity)Time frame: during the first 21-day cycle of HRS-4508 treatment
- MTD (Maximum tolerated dose)Time frame: 3 weeks after treatment initiation
- RP2D (Recommended Phase II Dose)Time frame: 3 weeks after treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.